Does D-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis (Q31171981)

5 November 2017

4 references

17 September 2019

2 October 2019

19 November 2019

29 January 2021

0 references

Does D-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis (English)

1 reference

5 November 2017

heterocyclic compound

1 reference

17 September 2019

3 references

17 September 2019

2 October 2019

19 November 2019

1 reference

2 October 2019

1 reference

19 November 2019

1 reference

29 January 2021

1 reference

1 reference

Helga Rodrigues

1

1 reference

5 November 2017

Ivan Figueira

2

1 reference

5 November 2017

Alessandra Lopes

3

1 reference

5 November 2017

Raquel Gonçalves

4

1 reference

5 November 2017

Mauro Vitor Mendlowicz

5

1 reference

5 November 2017

Evandro Silva Freire Coutinho

6

1 reference

5 November 2017

Paula Ventura

7

1 reference

5 November 2017

language of work or name

English

0 references

publication date

3 July 2014

5 references

5 November 2017

17 September 2019

2 October 2019

19 November 2019

29 January 2021

5 references

5 November 2017

17 September 2019

2 October 2019

19 November 2019

29 January 2021

9

1 reference

5 November 2017

7

1 reference

5 November 2017

e93519

1 reference

Creative Commons Attribution 4.0 International

5 November 2017

4 references

17 September 2019

2 October 2019

19 November 2019

D-Cycloserine as an augmentation strategy for cognitive behavioral therapy of anxiety disorders

29 January 2021

0 references

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

D-cycloserine as an augmentation strategy for cognitive behavioral therapy for anxiety disorders: an update

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

D-cycloserine augmentation of behavioral therapy for the treatment of anxiety disorders: a meta-analysis.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

Nonresponse and dropout rates in outcome studies on PTSD: review and methodological considerations

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

D-cycloserine augmented exposure therapy for obsessive-compulsive disorder

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

Novel treatment approaches for refractory anxiety disorders

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

Clinical perspectives on the combination of D-cycloserine and cognitive-behavioral therapy for the treatment of anxiety disorders.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

Treatment-resistant anxiety disorders

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

Randomized, Placebo-Controlled Trial of Exposure and Ritual Prevention, Clomipramine, and Their Combination in the Treatment of Obsessive-Compulsive Disorder

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

Cognitive-behavioral therapy for the treatment of anxiety disorders

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

Do patients drop out prematurely from exposure therapy for PTSD?

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

The epidemiology of anxiety disorders: prevalence and societal costs.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination?

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

Quantifying heterogeneity in a meta-analysis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

Quality of life in individuals with anxiety disorders

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

Multicenter Collaborative Panic Disorder Severity Scale

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

Definition and epidemiology of treatment-resistant depression

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

Desensitization of the NMDA receptor complex by glycinergic ligands in cerebellar granule cell cultures

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

28 July 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

28 July 2018

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0093519

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

Meta-analysis of dropout rates in SSRIs versus placebo in randomized clinical trials of PTSD.

28 July 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0093519

D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0093519

Exposure therapy, D-cycloserine, and functional magnetic resonance imaging in patients with snake phobia: a randomized pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0093519

Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0093519

d-Cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0093519

Augmentation of exposure therapy with D-cycloserine for social anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0093519

An empirically derived inventory to measure social fears and anxiety: The Social Phobia and Anxiety Inventory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0093519

A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0093519

A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0093519

Augmentation of cognitive behavioral therapy with pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0093519

Chronic treatment with antidepressants affects glycine/NMDA receptor function: behavioral evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0093519

Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0093519

Effects of D-cycloserine on extinction of conditioned freezing

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0093519

Need for speed: evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0093519

Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0093519

Harnessing N-methyl-d-aspartate receptors for new treatment development in psychiatry: positive lessons from negative studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0093519

Augmentation of exposure therapy with post-session administration of D-cycloserine

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

Consolidation of extinction learning involves transfer from NMDA-independent to NMDA-dependent memory.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

The economic burden of anxiety disorders in the 1990s

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081005

Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale

31 October 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0093519

A randomized placebo-controlled trial of D-cycloserine to enhance exposure therapy for posttraumatic stress disorder

21 January 2018

1 reference

12 December 2020

Treatment of social phobia through pure self-help and therapist-augmented self-help

1 reference

12 December 2020

A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia

1 reference

12 December 2020

IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans

1 reference

12 December 2020

10.1371/JOURNAL.PONE.0093519

Identifiers

DOI

1 reference

5 November 2017

0 references

0 references

1 reference

5 November 2017

PubMed publication ID

24991926

1 reference